about
Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and PrognosisHepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress ResponseHistorical review of the causes of cancerMetabolic alterations and hepatitis C: From bench to bedsideRheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosisHepatitis C and insulin action: An intimate relationshipEpidemiology of hepatitis C virus in IranDevelopment of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisionsTreatment for hepatitis B in patients with drug resistanceGeno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsInactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugsDaclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.New Therapies for Hepatitis C Virus Infection.Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms.Development of risky varices in alcoholic cirrhosis with a well-maintained nutritional status.Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.Hepatitis C virus infection: Are there still specific problems with genotype 3?Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological responseA Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway.Hepatitis C Virus Resistance to Carbohydrate-Binding AgentsNew prospects for the treatment and prevention of hepatitis C in children.Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan.HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.A Hepatitis C Educational Needs Assessment of Canadian Healthcare Providers.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals.Real world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.Impact of natural killer cells on chronic hepatitis C and hepatocellular carcinoma.Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.The expanding toolbox for hepatitis C virus research.Extracorporeal liver support devices for listed patients.Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.Protein Interactions during the Flavivirus and Hepacivirus Life Cycle.Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.Daclatasvir/Asunaprevir/Beclabuvir (DCV-TRIO), All-Oral, Fixed-Dose Combination for Patients With Chronic HCV Genotype 1.New Therapies for Hepatitis C Virus.
P2860
Q26740313-7477EB43-B864-4235-85ED-BDEA4825802DQ26745984-998A52E2-C4C7-4B0A-8282-A3B540C58875Q26767036-5AFD23DF-F59C-4886-90B4-3618D41A3438Q26773261-7784ACC7-6E91-4886-B9DB-B1E0235EE099Q26773278-F1B97B1A-2B3A-49BA-AC49-D9E0D9995AC3Q26775000-0B9C2CA3-5A55-4199-9282-D6D64EB3EA62Q26781996-4A04BCA2-EF9D-4E71-8C21-24979CF9D564Q27468990-728B689E-898A-4D44-837D-5606C6895427Q28072483-523ED47E-E4C6-425E-A262-8A25217551A2Q28552269-CFBCAF6C-7CCC-435C-81C7-CD29EFE61F9DQ30369227-A137A351-FC36-4C28-9093-5060A00D69CCQ31170657-979564AE-A69B-40A9-B30A-E0866A108E01Q33560181-C957BE7B-1E86-4F78-91D4-17A562D9A34EQ35828072-0E6ADDDA-3EFF-4689-B273-030554753DEDQ35994877-37083DEF-1EDF-4AD2-AF68-EA2474DF1016Q36080449-BC43DAF8-A8C1-4B01-AAA3-E0D753A43DBFQ36258800-9F5F7F62-9959-43DB-835B-6739B1D7DFC0Q36269670-B233B635-309B-42D3-8C53-DBE57B9D305EQ36280109-B31A6FA4-6A5F-4395-8752-E531A54A1194Q36540898-FCDFAC3C-AE1C-445E-A781-1FB95B7C51B9Q36576382-7F45EF79-65AB-43FA-8A36-2A4C89F08899Q36608054-0B653DB6-06CF-45BA-9385-48BB3C336696Q36997093-64FFEDC1-BE75-462B-8962-A5CA5C2E5A79Q37368417-BE368865-A92C-4C83-A043-4B224829829AQ37417839-F492071C-CE0F-42B7-B54A-E66281449CCAQ37726292-61E6BFB5-AEC2-40DE-AA70-23E2E646D893Q38602682-93C30F88-BEFD-427E-9587-69D621E83F77Q38611469-18F6B4D5-F30D-4B65-B9A2-FC01A077ABFFQ38620762-414F210C-C015-4CCB-91E0-74820443E068Q38635000-67BDA618-1CF5-450F-890E-52657B33C249Q38637199-0E445F36-0235-42EA-BD5A-92F30C9E0541Q38695199-535B64D9-006B-4036-888C-7BB84476B9CDQ38702799-5EA4B3AB-B1D4-4FA7-B348-0CB60C60A4DDQ38715318-D8B09FA7-4CC4-45EA-ADDB-48FC9AE53C50Q38719498-8D28EDE9-D609-4989-8617-F3F6B237B30AQ38751552-B864A6EF-13BB-4937-810D-50364CF8ADB6Q38771712-0B25DF6D-621F-4725-9E32-F665A0B56426Q38850319-465317A0-C4F0-49E0-8982-AF508EFFC653Q38859479-F5FB634C-8F3A-4C28-B805-75B297668C68Q38904248-FB1B4431-DCAE-462C-BA6E-6F64DD4C2A51
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
From non-A, non-B hepatitis to hepatitis C virus cure
@ast
From non-A, non-B hepatitis to hepatitis C virus cure
@en
From non-A, non-B hepatitis to hepatitis C virus cure
@nl
type
label
From non-A, non-B hepatitis to hepatitis C virus cure
@ast
From non-A, non-B hepatitis to hepatitis C virus cure
@en
From non-A, non-B hepatitis to hepatitis C virus cure
@nl
prefLabel
From non-A, non-B hepatitis to hepatitis C virus cure
@ast
From non-A, non-B hepatitis to hepatitis C virus cure
@en
From non-A, non-B hepatitis to hepatitis C virus cure
@nl
P3181
P1476
From non-A, non-B hepatitis to hepatitis C virus cure
@en
P2093
Jay H. Hoofnagle
Jordan J. Feld
P304
P3181
P356
10.1016/J.JHEP.2015.02.006
P407
P433
P577
2015-04-01T00:00:00Z